Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MG
MCID: MYS003
MIFTS: 74

Myasthenia Gravis (MG)

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Myasthenia Gravis

About this section

MalaCards integrated aliases for Myasthenia Gravis:

Name: Myasthenia Gravis 57 38 12 76 53 25 54 59 37 29 55 43 44 15 73
Mg 57 25
Autoimmune Myasthenia Gravis 59
Acquired Myasthenia 59

Characteristics:

Orphanet epidemiological data:

59
myasthenia gravis
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe),1-9/100000 (Worldwide),1-9/1000000 (United States),1-5/10000 (Canada),1-9/100000 (Spain),1-5/10000 (United Kingdom),1-9/100000 (United Kingdom),1-9/100000 (Serbia),1-5/10000 (United States),1-5/10000 (Serbia),1-9/100000 (Italy),1-5/10000 (Austria),1-9/100000 (Australia),1-5/10000 (Italy),1-9/100000 (Taiwan, Province of China),1-5/10000 (Australia),1-9/1000000 (Greece),1-5/10000 (Taiwan, Province of China),1-9/1000000 (Croatia),1-9/100000 (Estonia),1-9/100000 (Greece),1-9/100000 (Croatia),1-9/100000 (Egypt),1-9/1000000 (Worldwide); Age of onset: All ages; Age of death: normal life expectancy;

OMIM:

57
Inheritance:
usually sporadic
1 to 4 % of cases are familial without a simple mendelian pattern
familial predisposition may be due to autoimmunity in general.


Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Eye diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare neurological diseases
Rare eye diseases


Sources

Summaries for Myasthenia Gravis

About this section
NINDS : 54 Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal muscles of the body, which are responsble for breathing and moving parts of the body. In myasthenia gravis, the immune system--which normally protects the body from foreign organisms--mistakenly attacks itself.  Symptoms vary in type and intensity. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Certain muscles that control eye and eyelid movements, facial expression, chewing, talking, and swallowing are often, but not always, involved. The muscles that control breathing and neck and limb movements may also be affected. Myasthenia gravis is caused by a defect in the transmission of nerve impulses to muscles. Normally when impulses travel down the nerve, the nerve endings release a neurotransmitter substance called acetylcholine. In myasthenia gravis, antibodies produced by the body's own immune system block, alter, or destroy the receptors for acetylcholine. The first noticeable symptoms of myasthenia gravis may be weakness of the eye muscles, difficulty in swallowing, or slurred speech. Other symptoms may include blurred or double vision, drooping eyelid(s), and weakness in the arms, hands, fingers, legs, and neck. Myasthenia gravis is not directly inherited nor is it contagious.

MalaCards based summary : Myasthenia Gravis, also known as mg, is related to neonatal myasthenia gravis and neuromuscular disease, and has symptoms including seizures, muscle weakness and tremor. An important gene associated with Myasthenia Gravis is AKAP12 (A-Kinase Anchoring Protein 12), and among its related pathways/superpathways are Allograft rejection and Immune response NFAT in immune response. The drugs Azathioprine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include thymus, eye and skeletal muscle, and related phenotypes are ptosis and diplopia

Genetics Home Reference : 25 Myasthenia gravis is a disorder that causes weakness of the skeletal muscles, which are muscles that the body uses for movement. The weakness most often starts in the muscles around the eyes, causing drooping of the eyelids (ptosis) and difficulty coordinating eye movements, which results in blurred or double vision. In a form of the disorder called ocular myasthenia, the weakness remains confined to the eye muscles. In most people with myasthenia gravis, however, additional muscles in the face and neck are affected. Affected individuals may have unusual facial expressions, difficulty holding up the head, speech impairment (dysarthria), and chewing and swallowing problems (dysphagia) that may lead to choking, gagging, or drooling.

NIH Rare Diseases : 53 Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. Common symptoms include weakness of the muscles that control the eye and eyelid, facial expressions, chewing, talking, and swallowing. Weakness tends to increase during periods of activity and improve after periods of rest. The condition results from a defect in the transmission of nerve impulses to muscles, which is due to the presence of antibodies against acetylcholine. The exact reason this occurs is not known. Some cases have been linked to tumors in the thymus gland. Researchers believe that variations in certain genes may increase a person's risk to develop MG, but other factors likely also play a role. There is no cure for MG at this time, but treatment can significantly improve muscle weakness. Some cases may go into remission temporarily, and muscle weakness may disappear so that medications can be discontinued.

MedlinePlus : 43 Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest. Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker. Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps. Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 76 Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal... more...

Description from OMIM: 254200
Sources

Related Diseases for Myasthenia Gravis

About this section

Diseases in the Myasthenia Gravis family:

Myasthenia Gravis Congenital Juvenile Myasthenia Gravis
Adult-Onset Myasthenia Gravis

Diseases related to Myasthenia Gravis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 609)
# Related Disease Score Top Affiliating Genes
1 neonatal myasthenia gravis 34.3 CHRNG MUSK
2 neuromuscular disease 33.1 MUSK RYR1 TTN
3 thymoma 32.6 AIRE CTLA4 IL2 RYR1 TTN
4 congenital myasthenic syndrome 32.6 ACHE AGRN CHRNA1 CHRNE CHRNG MUSK
5 ptosis 30.8 CHRNA1 CHRNE MUSK RAPSN RYR1
6 meningitis 30.6 IFNG IL10 TNF
7 postsynaptic congenital myasthenic syndromes 30.4 AGRN CHRNA1 CHRNE MUSK RAPSN
8 rheumatic disease 30.3 IFNG IL10 TNF
9 transverse myelitis 30.3 IL10 MBP TNF
10 viral infectious disease 30.2 IFNG IL10 IL2 IL4 TNF
11 microscopic polyangiitis 30.2 IL10 TNF
12 aseptic meningitis 30.2 IFNG IL10 TNF
13 lichen planus 30.2 IFNG IL4 TNF
14 hashimoto thyroiditis 30.2 AIRE CTLA4 IFNG IL4
15 demyelinating disease 30.2 IFNG IL10 MBP TNF
16 aplastic anemia 30.1 IFNG IL2 IL4 TNF
17 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.1 AIRE CTLA4 IFNG IL10 TNFSF13B
18 polyradiculoneuropathy 30.1 IFNG IL10 MBP
19 systemic lupus erythematosus 30.1 CTLA4 IFNG IL10 IL2 IL4 TNF
20 candidiasis 30.1 AIRE IFNG IL10
21 autoimmune addison disease 30.1 AIRE CTLA4
22 celiac disease 1 30.0 CTLA4 IFNG IL10 IL2 TNF
23 connective tissue disease 30.0 IFNG IL10 TNF TNFSF13B
24 otitis media 30.0 IL10 IL4 TNF
25 interstitial lung disease 30.0 IFNG IL10 IL4 TNF
26 alopecia areata 30.0 AIRE CTLA4 IFNG IL2 TNF
27 mixed connective tissue disease 29.9 IFNG IL10 TNF
28 tetanus 29.9 IFNG IL10 IL2 IL4
29 hematopoietic stem cell transplantation 29.9 CTLA4 IFNG IL10 IL2 TNF
30 scleritis 29.9 IFNG IL4 TNF
31 bronchiolitis obliterans 29.9 IFNG IL10 TNF
32 uveitis 29.9 CTLA4 IFNG IL10 IL4 TNF
33 rasmussen encephalitis 29.9 IFNG IL4 TNF
34 conjunctivitis 29.9 IFNG IL2 IL4
35 psoriasis 29.8 IFNG IL10 IL2 IL4 TNF
36 hemophagocytic lymphohistiocytosis 29.8 CTLA4 IFNG IL10 TNF
37 rheumatoid arthritis 29.8 CTLA4 IFNG IL10 IL2 IL4 TNF
38 lepromatous leprosy 29.8 IFNG IL10 IL2 TNF
39 human immunodeficiency virus infectious disease 29.8 IFNG IL10 IL2 TNF
40 graft-versus-host disease 29.8 IFNG IL10 IL2 TNF
41 poliomyelitis 29.8 IFNG IL10 IL4 TNF
42 lymphadenitis 29.8 IFNG IL10 TNF
43 toxoplasmosis 29.8 IFNG IL10 IL4 TNF
44 bronchiolitis 29.8 IFNG IL10 IL4 TNF
45 primary progressive multiple sclerosis 29.8 IL10 MBP TNF
46 progressive multifocal leukoencephalopathy 29.8 IL2 MBP TNF
47 renal cell carcinoma, nonpapillary 29.8 CTLA4 IFNG IL2 IL4
48 chronic mucocutaneous candidiasis 29.7 AIRE IFNG IL10 TNF
49 multiple sclerosis 29.6 CTLA4 IFNG IL10 IL2 IL4 MBP
50 neuritis 29.6 IFNG IL4 MBP TNF

Graphical network of the top 20 diseases related to Myasthenia Gravis:



Diseases related to Myasthenia Gravis
Sources

Symptoms & Phenotypes for Myasthenia Gravis

About this section

Symptoms via clinical synopsis from OMIM:

57
H E E N T:
ptosis
diplopia
dysarthria
facial muscle weakness
difficulty chewing

Immunology:
autoimmunity
thymoma
antibodies to acetylcholine receptor (achr)
association with gm type

Muscle:
proximal limb muscle weakness.

Pulmonary:
ventilatory insufficiency

G I:
dysphagia

Voice:
nasal speech

Endocrine:
thyrotoxicosis

Misc:
childhood or adolescent onset
static or only slowly progressive


Clinical features from OMIM:

254200

Human phenotypes related to Myasthenia Gravis:

59 32 (show all 39)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ptosis 59 32 frequent (33%) Frequent (79-30%) HP:0000508
2 diplopia 59 32 frequent (33%) Frequent (79-30%) HP:0000651
3 seizures 59 32 very rare (1%) Very rare (<4-1%) HP:0001250
4 dysarthria 59 32 frequent (33%) Frequent (79-30%) HP:0001260
5 dysphagia 59 32 frequent (33%) Frequent (79-30%) HP:0002015
6 hearing impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0000365
7 acrocyanosis 59 32 very rare (1%) Very rare (<4-1%) HP:0001063
8 dyspnea 59 32 frequent (33%) Frequent (79-30%) HP:0002094
9 hepatitis 59 32 very rare (1%) Very rare (<4-1%) HP:0012115
10 hemolytic anemia 59 32 very rare (1%) Very rare (<4-1%) HP:0001878
11 hashimoto thyroiditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000872
12 ophthalmoparesis 59 32 frequent (33%) Frequent (79-30%) HP:0000597
13 hyperthyroidism 59 32 occasional (7.5%) Occasional (29-5%) HP:0000836
14 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
15 primary adrenal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0008207
16 psychosis 59 32 very rare (1%) Very rare (<4-1%) HP:0000709
17 hyperacusis 59 32 occasional (7.5%) Occasional (29-5%) HP:0010780
18 myositis 59 32 frequent (33%) Frequent (79-30%) HP:0100614
19 abnormality of the thymus 59 32 frequent (33%) Frequent (79-30%) HP:0000777
20 bulbar palsy 59 32 frequent (33%) Frequent (79-30%) HP:0001283
21 single fiber emg abnormality 59 32 frequent (33%) Frequent (79-30%) HP:0030006
22 acetylcholine receptor antibody positivity 59 32 frequent (33%) Frequent (79-30%) HP:0030208
23 muscle specific kinase antibody positivity 59 32 frequent (33%) Frequent (79-30%) HP:0030210
24 rheumatoid arthritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001370
25 systemic lupus erythematosus 59 32 occasional (7.5%) Occasional (29-5%) HP:0002725
26 glycosuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0003076
27 raynaud phenomenon 59 32 occasional (7.5%) Occasional (29-5%) HP:0030880
28 pure red cell aplasia 59 32 very rare (1%) Very rare (<4-1%) HP:0012410
29 muscle weakness 59 Very frequent (99-80%)
30 facial palsy 32 HP:0010628
31 autoimmunity 32 HP:0002960
32 abnormality of the endocrine system 32 HP:0000818
33 abnormality of the immune system 32 HP:0002715
34 nasal speech 32 HP:0001611
35 thymoma 32 HP:0100522
36 proximal muscle weakness 32 HP:0003701
37 limb muscle weakness 32 HP:0003690
38 fatigable weakness 32 HP:0003473
39 impaired mastication 32 HP:0005216

UMLS symptoms related to Myasthenia Gravis:


seizures, muscle weakness, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, facial paresis, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

26 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.95 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.95 TNFSF13B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.95 ACHE
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.95 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.95 IL10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.95 MUSK
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.95 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.95 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.95 ACHE
10 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.95 TNFSF13B
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.95 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.95 ACHE AIRE IL10 MUSK TNFSF13B
13 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.95 AIRE
14 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.95 TNFSF13B
15 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.95 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.95 MUSK
17 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.95 MUSK
18 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.95 IL10
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.95 ACHE IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.95 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.95 MUSK
22 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.95 TNFSF13B
23 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.95 TNFSF13B
24 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.95 MUSK
25 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.95 AIRE
26 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.95 IL10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.95 MUSK
28 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.95 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.95 ACHE MUSK
30 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.95 TNFSF13B
31 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.95 AIRE IL10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.95 IL10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.95 AIRE IL10 MUSK
34 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.5 TMPO
35 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 9.5 TMPO
36 Decreased shRNA abundance (Z-score < -2) GR00366-A-155 9.5 CHRNA1 RAPSN TMPO
37 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.5 TMPO
38 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.5 TMPO

MGI Mouse Phenotypes related to Myasthenia Gravis:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.46 ACHE AGRN AIRE AKAP12 CHRNA1 CHRNE
2 mortality/aging MP:0010768 10.41 ACHE AGRN AIRE AKAP12 CHRNA1 CHRNE
3 homeostasis/metabolism MP:0005376 10.4 ACHE AGRN AIRE CHRNG CTLA4 IFNG
4 growth/size/body region MP:0005378 10.39 ACHE AGRN AIRE CHRNE CHRNG IFNG
5 hematopoietic system MP:0005397 10.31 ACHE AIRE AKAP12 CTLA4 IFNG IL10
6 immune system MP:0005387 10.25 AIRE AKAP12 CTLA4 IFNG IL10 IL2
7 nervous system MP:0003631 10.25 ACHE AGRN AIRE AKAP12 CHRNA1 CHRNE
8 digestive/alimentary MP:0005381 10.22 AIRE CTLA4 IFNG IL10 IL2 IL4
9 endocrine/exocrine gland MP:0005379 10.21 AIRE AKAP12 CTLA4 IFNG IL10 IL2
10 muscle MP:0005369 10.21 ACHE AGRN AKAP12 CHRNE CHRNG IFNG
11 integument MP:0010771 10.15 CHRNG CTLA4 IFNG IL10 IL4 MUSK
12 craniofacial MP:0005382 10.12 ACHE IFNG IL10 IL4 RYR1 TNF
13 liver/biliary system MP:0005370 10.08 AIRE AKAP12 CTLA4 IFNG IL10 IL2
14 respiratory system MP:0005388 10.03 ACHE AGRN AIRE AKAP12 CHRNE CHRNG
15 no phenotypic analysis MP:0003012 9.97 ACHE AIRE CHRNE IFNG IL10 IL2
16 normal MP:0002873 9.97 AGRN AIRE AKAP12 CTLA4 IFNG IL10
17 reproductive system MP:0005389 9.91 ACHE AIRE AKAP12 IFNG IL10 IL2
18 skeleton MP:0005390 9.61 CHRNA1 CTLA4 IFNG IL10 IL4 MUSK
19 vision/eye MP:0005391 9.28 ACHE AIRE IFNG IL10 IL2 IL4
Sources

Drugs & Therapeutics for Myasthenia Gravis

About this section

Drugs for Myasthenia Gravis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4,Phase 3,Not Applicable 446-86-6 2265
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 53-03-2 5865
3 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
4 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
5 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
7 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Not Applicable
8 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
9 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
10 Immunoglobulins Phase 4,Phase 3,Phase 2,Not Applicable
11 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
12 Antibodies Phase 4,Phase 3,Phase 2,Not Applicable
13 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
15 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1
16 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
17 Hormones Phase 4,Phase 3,Phase 2,Phase 1
18 glucocorticoids Phase 4,Phase 3,Phase 1
19 Pyridostigmine Bromide Phase 4,Phase 3,Phase 2,Not Applicable 101-26-8
20 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Bromides Phase 4,Phase 3,Phase 2,Not Applicable
22 Cholinergic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
23 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
24
Mycophenolic acid Approved Phase 3,Not Applicable 24280-93-1 446541
25
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1 83-43-2 6741
26
Prednisolone Approved, Vet_approved Phase 3,Phase 1 50-24-8 5755
27
Methylprednisolone hemisuccinate Approved Phase 3,Phase 1 2921-57-5
28
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 1 302-25-0
29
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492
30
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
31
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
32 tannic acid Approved Phase 3
33
4-Aminopyridine Approved Phase 3 504-24-5 1727
34
Rocuronium Approved Phase 3 119302-91-9, 143558-00-3 441290
35
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
36
Acetylcholine Approved Phase 3,Phase 1,Phase 2 51-84-3 187
37
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
38
Aluminum hydroxide Approved, Investigational Phase 2, Phase 3,Phase 1 21645-51-2
39
Prednisolone hemisuccinate Experimental Phase 3,Phase 1 2920-86-7
40 Antibiotics, Antitubercular Phase 3,Not Applicable
41 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
42 Anti-Bacterial Agents Phase 3,Not Applicable
43 Antitubercular Agents Phase 3,Not Applicable
44 Vaccines Phase 3,Phase 1,Phase 2
45 Methylprednisolone acetate Phase 3,Phase 1
46 Prednisolone acetate Phase 3,Phase 1
47 Calcineurin Inhibitors Phase 3
48 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
49 Potassium Channel Blockers Phase 3
50 3,4-diaminopyridine Phase 3

Interventional clinical trials:

(show top 50) (show all 86)
# Name Status NCT ID Phase Drugs
1 Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis Completed NCT01179893 Phase 4
2 Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis Completed NCT00987116 Phase 4 Prednisone - Azathioprine
3 Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis Recruiting NCT03510546 Phase 4 Pyridostigmine;Placebo oral capsule
4 Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) Completed NCT01997229 Phase 3 Placebo
5 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Completed NCT00294658 Phase 3 prednisone alone
6 A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations Completed NCT02413580 Phase 3
7 Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis Completed NCT00306033 Phase 3 Intravenous ImmuneGlobulin
8 A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis Completed NCT01325571 Phase 3 Tacrolimus capsule;Placebo
9 Mycophenolate Mofetil in Myasthenia Gravis Completed NCT00285350 Phase 3 mycophenolate mofetil
10 Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis Completed NCT00515450 Phase 3
11 FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients Completed NCT00309088 Phase 3 tacrolimus;placebo
12 A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis. Completed NCT00408213 Phase 3 mycophenolate mofetil [CellCept];Placebo
13 A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis Completed NCT00683969 Phase 3 mycophenolate mofetil (CellCept);placebo
14 An Open Study for Steroid Resistant, Non-Thymectomized MG Patients Completed NCT00309101 Phase 3 tacrolimus
15 Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Completed NCT02970162 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
16 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Completed NCT01377922 Phase 3 Amifampridine Phosphate;Placebo
17 Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest Completed NCT01719770 Phase 3 rocuronium
18 An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness Recruiting NCT03669588 Phase 3
19 A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis Recruiting NCT02950155 Phase 3 Rituximab;Sodium Chloride solution
20 A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) Recruiting NCT02774239 Phase 3 Human normal immunoglobulin G (IgG)
21 The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Recruiting NCT01727193 Phase 3 Azathioprine;Leflunomide
22 Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Recruiting NCT03304054 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
23 Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis) Recruiting NCT03579966 Phase 3 Amifampridine Phosphate
24 ECU-MG-302: An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis Active, not recruiting NCT02301624 Phase 3
25 A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG) Not yet recruiting NCT03759366 Phase 3 Eculizumab
26 A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. Not yet recruiting NCT03770403 Phase 3
27 Efficacy of Prednisone In the Treatment of Ocular Myasthenia Terminated NCT00995722 Phase 3 Prednisone;Placebo
28 A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis Withdrawn NCT03165435 Phase 2, Phase 3
29 Sulfamethoxazole for the Treatment of Primary PREPL Deficiency Unknown status NCT02640443 Phase 2 Sulfamethoxazole
30 Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis. Completed NCT03052751 Phase 2 UCB7665
31 BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis Completed NCT02110706 Phase 2 Rituximab;Placebo
32 Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis Completed NCT02565576 Phase 2 Placebo;CFZ533
33 Efficacy of Methotrexate in Myasthenia Gravis Completed NCT00814138 Phase 2 Methotrexate
34 A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis Completed NCT02473952 Phase 2 IGIV-C;Placebo
35 A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness Completed NCT02965573 Phase 2 Placebo
36 A Pilot Trial of Rituxan in Refractory Myasthenia Gravis Completed NCT00619671 Phase 1, Phase 2 Rituximab (Rituxan)
37 The Evaluation of Belimumab in Myasthenia Gravis (MG) Completed NCT01480596 Phase 2
38 Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
39 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure Completed NCT03174964 Phase 2 IVIg
40 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
41 A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis Recruiting NCT03772587 Phase 2 M281
42 The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor Recruiting NCT02317224 Phase 2
43 Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) Recruiting NCT02102594 Phase 2 Bortezomib
44 Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis Active, not recruiting NCT03315130 Phase 2 RA101495;Placebo
45 Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis Active, not recruiting NCT02609022 Phase 1, Phase 2
46 Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis Active, not recruiting NCT02100969 Phase 2 HIZENTRA ®
47 Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis Active, not recruiting NCT02473965 Phase 2 IGIV-C;Placebo
48 Pyridostigmine as Immunomodulator in People Living With HIV Active, not recruiting NCT03312244 Phase 2 Pyridostigmine Bromide;Placebo
49 Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Terminated NCT00727194 Phase 2 eculizumab;Placebo
50 Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis Terminated NCT01268280 Phase 2 Placebo;250 mg CK-2017357;500 mg CK-2017357

Search NIH Clinical Center for Myasthenia Gravis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myasthenia Gravis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myasthenia Gravis:
Hematopoietic stem cells for refractory myasthenia gravis
Embryonic/Adult Cultured Cells Related to Myasthenia Gravis:
Peripheral blood-derived hematopoietic stem cells

Cochrane evidence based reviews: myasthenia gravis

Sources

Genetic Tests for Myasthenia Gravis

About this section

Genetic tests related to Myasthenia Gravis:

# Genetic test Affiliating Genes
1 Myasthenia Gravis 29
Sources

Anatomical Context for Myasthenia Gravis

About this section

MalaCards organs/tissues related to Myasthenia Gravis:

41
Thymus, Eye, Skeletal Muscle, Testes, T Cells, B Cells, Thyroid
Sources

Publications for Myasthenia Gravis

About this section

Articles related to Myasthenia Gravis:

(show top 50) (show all 2871)
# Title Authors Year
1
Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody. ( 30528803 )
2019
2
Management of Myasthenia Gravis in Pregnancy. ( 30470270 )
2019
3
Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: A life-threatening continuum of neuromuscular and cardiac toxicity. ( 30533536 )
2019
4
Relapsed Myasthenia Gravis after Nivolumab Treatment. ( 29434145 )
2018
5
The thymidylate synthase enhancer region (TSER) polymorphism increases the risk of thymic lymphoid hyperplasia in patients with Myasthenia Gravis. ( 29162511 )
2018
6
Whole-exome sequencing reveals a rare interferon gamma receptor 1 mutation associated with myasthenia gravis. ( 29441481 )
2018
7
Occipitalis muscle: using for repetitive facial nerve stimulation in myasthenia gravis. ( 29428994 )
2018
8
Myasthenia gravis: the unmet needs of a paradigmatic autoimmune disease. ( 29943694 )
2018
9
Effect of Qiangji Jianli decoction on mitochondrial respiratory chain activity and expression of mitochondrial fusion and fission proteins in myasthenia gravis rats. ( 29872094 )
2018
10
Introducing Autoimmunity at the Synapse by a Novel Animal Model of Experimental Autoimmune Myasthenia Gravis. ( 29421431 )
2018
11
Antibody profile may predict outcome in ocular myasthenia gravis. ( 29858757 )
2018
12
Thymus imaging in myasthenia gravis - the relevance in clinical practice. ( 29424940 )
2018
13
Survival and mortality of adult-onset myasthenia gravis in the population of Belgrade, Serbia. ( 29572981 )
2018
14
Evaluating the temperature effects of ice and heat tests on ptosis due to Myasthenia Gravis. ( 29743585 )
2018
15
Perianesthetic Implications and Considerations for Myasthenia Gravis. ( 29980408 )
2018
16
3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome. ( 29402568 )
2018
17
An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients. ( 29405352 )
2018
18
Respiratory insufficiency from myasthenia gravis and polymyositis due to malignant thymoma triggering Takotsubo syndrome. ( 29883223 )
2018
19
Administration of bifidobacterium and lactobacillus strains modulates experimental myasthenia gravis and experimental encephalomyelitis in Lewis rats. ( 29854277 )
2018
20
Myasthenia Gravis Complicated with Peripheral T-cell Lymphoma, Not Otherwise Specified (PTCL-NOS), Following Thymectomy and Longstanding Tacrolimus Therapy. ( 29269644 )
2018
21
Efficacy of Gaze Photographs in Diagnosing Ocular Myasthenia Gravis. ( 29856158 )
2018
22
Serum Acetylcholine Receptor Antibodies Before the Clinical Onset of Myasthenia Gravis. ( 29865092 )
2018
23
Giant Cell Polymyositis and Myocarditis in a Patient With Thymoma and Myasthenia Gravis: A Postviral Autoimmune Process? ( 29850899 )
2018
24
Autologous Bone Marrow Transplantation for Polymyositis Combined with Myasthenia Gravis and Aplastic Anemia: A Case Report. ( 29805377 )
2018
25
Eculizumab: A Review in Generalized Myasthenia Gravis. ( 29435915 )
2018
26
Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. ( 29903623 )
2018
27
Increased Proportion of Tc17 and Th17 Cells and Their Significant Reduction after Thymectomy May Be Related to Disease Progression in Myasthenia Gravis. ( 29414833 )
2018
28
Open source modular ptosis crutch for the treatment of myasthenia gravis. ( 29271663 )
2018
29
The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis. ( 29928654 )
2018
30
Combined operation for thymoma with myasthenia gravis and coronary artery disease in an octogenarian. ( 29924495 )
2018
31
A Physical and Psychological Approach to Managing Fatigue in Myasthenia Gravis: A Pilot Study. ( 29889078 )
2018
32
Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats. ( 29944018 )
2018
33
Ocular vestibular evoked myogenic potential in patients with myasthenia gravis: A prospective clinical study. ( 28662779 )
2018
34
Muscle strength and psychiatric symptoms influence health-related quality of life in patients with myasthenia gravis. ( 29396072 )
2018
35
Thymoma-associated myasthenia gravis and LGI1-encephalitis, with nephrotic syndrome post-thymectomy. ( 29395322 )
2018
36
Concurrent inflammatory myopathy and myasthenia gravis with or without thymic pathology: A case series and literature review. ( 29958689 )
2018
37
Passive transfer models of myasthenia gravis with muscle-specific kinase antibodies. ( 29356029 )
2018
38
When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. ( 29403543 )
2018
39
Prognosis of Ocular Myasthenia Gravis in an Argentinian Population. ( 29428956 )
2018
40
Characteristics, incidence, and outcome of patients admitted to the intensive care unit with myasthenia gravis. ( 29413729 )
2018
41
Correction: Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features. ( 29958297 )
2018
42
Comparative clinical outcomes after thymectomy for myasthenia gravis: Thoracoscopic versus trans-sternal approach. ( 27810167 )
2018
43
Thymectomy in nonthymomatous myasthenia gravis - systematic review and meta-analysis. ( 29940999 )
2018
44
Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China. ( 29535672 )
2018
45
Myasthenia gravis appearing after thymectomy heralding recurrent thymoma. ( 29768973 )
2018
46
Coexistence of myasthenia gravis and Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient: A case report. ( 29879051 )
2018
47
Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis. ( 29865089 )
2018
48
A Well-Tolerated and Effective Antiepileptic Drug for Patients With Myasthenia Gravis at Last? ( 29432285 )
2018
49
Myasthenia gravis with antibodies to MuSK: an update. ( 29266255 )
2018
50
Dysphagia in myasthenia gravis: the tip of the Iceberg. ( 29417423 )
2018
Sources

Variations for Myasthenia Gravis

About this section
Sources

Expression for Myasthenia Gravis

About this section
Search GEO for disease gene expression data for Myasthenia Gravis.
Sources

Pathways for Myasthenia Gravis

About this section

Pathways related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Allograft rejection 1 37
Show member pathways
 12.82 CTLA4 IFNG IL10 IL2 IL4 TNF
2
Immune response NFAT in immune response 22
Show member pathways
 12.6 IFNG IL10 IL2 IL4 TNF
3
Th17 cell differentiation 37
Show member pathways
 12.55 IFNG IL10 IL2 IL4 TNF
4
NF-kappaB Signaling 4
12.38 CTLA4 IFNG IL10 IL2 IL4 TNF
5
T cell receptor signaling pathway 37
Show member pathways
 12.34 CTLA4 IFNG IL10 IL2 IL4 TNF
6
Selenium Micronutrient Network 1
Show member pathways
 12.3 IFNG IL2 IL4 TNF
7
Toxoplasmosis 37
Show member pathways
 12.22 IFNG IL10 IL4 TNF
8
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.22 IFNG IL10 IL2 IL4 TNF
9
Immune response IFN gamma signaling pathway 22
Show member pathways
 12.04 IFNG IL10 IL2 IL4 TNFSF13B
10
Th1 Differentiation Pathway 65
Show member pathways
 12.02 IFNG IL10 IL2 TNF
11
Microglia Activation During Neuroinflammation: Overview 65
Show member pathways
 11.99 AGRN IFNG IL4 TNF
12
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.9 IFNG IL10 IL2 IL4 TNF
13
Amoebiasis 37
11.83 IFNG IL10 TNF
14
Rheumatoid arthritis 37
11.81 CTLA4 IFNG TNF TNFSF13B
15
Postsynaptic nicotinic acetylcholine receptors 66
Show member pathways
 11.77 CHRNA1 CHRNE CHRNG
16
Glucocorticoid receptor regulatory network 1
11.76 IFNG IL2 IL4
17
Dendritic Cells Developmental Lineage Pathway 65
11.72 IFNG IL10 IL2 TNF
18
Innate Lymphoid Cell Differentiation Pathways 65
11.67 IFNG IL10 IL2 IL4 TNF
19
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.63 IFNG IL2 TNF
20
Downstream signaling in naive CD8+ T cells 1
Show member pathways
 11.62 IFNG IL2 TNF
21
Agrin Interactions at Neuromuscular Junction 64
11.55 AGRN CHRNA1 MUSK RAPSN
22
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.54 CTLA4 IFNG IL2 IL4 TNF
23
Photodynamic therapy-induced AP-1 survival signaling. 1
11.53 IFNG IL2 TNF
24
Spinal Cord Injury 1
11.51 IFNG IL2 IL4 MBP TNF TNFSF13B
25
Interleukin-10 signaling 66
11.5 IL10 IL4 TNF
26
Malaria 37
11.5 IFNG IL10 TNF
27
Aryl Hydrocarbon Receptor Pathway 1
11.48 IFNG IL2 TNF
28
Th2 Differentiation Pathway 65
11.44 IFNG IL10 IL2 IL4
29
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.4 IFNG IL10 IL2 IL4 TNF
30
African trypanosomiasis 37
11.31 IFNG IL10 TNF
31
Inflammatory Response Pathway 1
11.27 IFNG IL2 IL4
32
Development and heterogeneity of the ILC family 1
11.25 IFNG IL4 TNF
33
G-protein signaling_RhoB regulation pathway 22
11.15 IL10 IL2 IL4 TNF TNFSF13B
34
OX40 Pathway 64
11.12 IFNG IL10 IL2 IL4
35
G-protein signaling_Rap2B regulation pathway 22
10.98 IL10 IL2 IL4 MUSK TNF TNFSF13B
36
Succinylcholine Pathway, Pharmacokinetics/Pharmacodynamics 61
10.77 CHRNA1 CHRNE RYR1
37
Cytokines and Inflammatory Response 1
10.48 IFNG IL10 IL2 IL4 TNF
Sources

GO Terms for Myasthenia Gravis

About this section

Cellular components related to Myasthenia Gravis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.98 CHRNA1 CHRNE CHRNG CTLA4 MUSK RYR1
2 cell junction GO:0030054 9.87 ACHE AGRN CHRNA1 CHRNE CHRNG MUSK
3 postsynaptic membrane GO:0045211 9.65 CHRNA1 CHRNE CHRNG MUSK RAPSN
4 synapse GO:0045202 9.5 ACHE AGRN CHRNA1 CHRNE CHRNG MUSK
5 acetylcholine-gated channel complex GO:0005892 9.33 CHRNA1 CHRNE CHRNG
6 neuromuscular junction GO:0031594 9.02 ACHE CHRNA1 CHRNE MUSK RAPSN
7 plasma membrane GO:0005886 10.18 ACHE AGRN AKAP12 CHRNA1 CHRNE CHRNG
8 extracellular region GO:0005576 10.06 ACHE AGRN IFNG IL10 IL2 IL4

Biological processes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.94 CHRNA1 CHRNE CHRNG RYR1
2 positive regulation of protein phosphorylation GO:0001934 9.88 IFNG IL2 MUSK TNF
3 excitatory postsynaptic potential GO:0060079 9.8 CHRNA1 CHRNE CHRNG
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 IFNG IL2 IL4
5 positive regulation of T cell proliferation GO:0042102 9.78 IL2 IL4 TNFSF13B
6 humoral immune response GO:0006959 9.77 AIRE IFNG TNF
7 chemical synaptic transmission GO:0007268 9.77 CHRNA1 CHRNE CHRNG MBP RAPSN
8 nervous system process GO:0050877 9.75 CHRNA1 CHRNE CHRNG
9 regulation of postsynaptic membrane potential GO:0060078 9.73 CHRNA1 CHRNE CHRNG
10 regulation of signaling receptor activity GO:0010469 9.73 IFNG IL10 IL2 IL4 TNF TNFSF13B
11 muscle contraction GO:0006936 9.71 CHRNE CHRNG RYR1 TTN
12 response to nicotine GO:0035094 9.69 CHRNA1 CHRNE CHRNG
13 positive regulation of B cell proliferation GO:0030890 9.67 IL2 IL4 TNFSF13B
14 negative regulation of growth of symbiont in host GO:0044130 9.65 IL10 TNF
15 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.65 IL10 TNF
16 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.64 IL10 MBP
17 positive regulation of isotype switching to IgG isotypes GO:0048304 9.63 IL2 IL4
18 endothelial cell apoptotic process GO:0072577 9.62 IL10 TNF
19 neuromuscular synaptic transmission GO:0007274 9.61 CHRNA1 CHRNE CHRNG
20 positive regulation of MHC class II biosynthetic process GO:0045348 9.6 IL10 IL4
21 negative regulation of cytokine secretion involved in immune response GO:0002740 9.57 IL10 TNF
22 regulation of synaptic growth at neuromuscular junction GO:0008582 9.55 AGRN MUSK
23 regulation of isotype switching GO:0045191 9.54 IL10 IL4
24 type 2 immune response GO:0042092 9.52 IL10 IL4
25 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 IFNG TNF
26 receptor biosynthetic process GO:0032800 9.46 IL10 TNF
27 regulation of regulatory T cell differentiation GO:0045589 9.33 CTLA4 IFNG IL2
28 positive regulation of vitamin D biosynthetic process GO:0060557 9.32 IFNG TNF
29 immune response GO:0006955 9.28 AIRE CTLA4 IFNG IL10 IL2 IL4
30 synaptic transmission, cholinergic GO:0007271 9.26 CHRNA1 CHRNE CHRNG RAPSN
31 positive regulation of gene expression GO:0010628 10.01 IFNG IL4 MUSK TNF TTN

Molecular functions related to Myasthenia Gravis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion channel activity GO:0005216 9.71 CHRNA1 CHRNE CHRNG RYR1
2 protease binding GO:0002020 9.62 MBP RYR1 TNF TTN
3 extracellular ligand-gated ion channel activity GO:0005230 9.61 CHRNA1 CHRNE CHRNG
4 ligand-gated ion channel activity GO:0015276 9.54 CHRNA1 CHRNE CHRNG
5 acetylcholine-gated cation-selective channel activity GO:0022848 9.43 CHRNA1 CHRNE CHRNG
6 cytokine activity GO:0005125 9.43 IFNG IL10 IL2 IL4 TNF TNFSF13B
7 acetylcholine receptor activity GO:0015464 9.33 CHRNA1 CHRNE CHRNG
8 acetylcholine binding GO:0042166 8.92 ACHE CHRNA1 CHRNE CHRNG
9 protein binding GO:0005515 10.39 ACHE AGRN AIRE AKAP12 CHRNG CTLA4
Sources

Sources for Myasthenia Gravis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....